
    
      The drug being studied in this study is called alogliptin and alogliptin FDCs. Alogliptin and
      alogliptin FDCs is being researched to treat people who have diabetes mellitus type 2. This
      study will look at the glycosylated hemoglobin (HbA1c) level dynamics in participants with
      diabetes mellitus type 2.

      The study enrolled 593 patients. Alogliptin and alogliptin FDCs will be prescribed by the
      physician as part of participants' T2DM treatment program (independent of participation in
      this study).

      This multi-center study will be conducted in China. The overall duration of study for
      observation will be approximately 6 months, or up to loss to follow-up or death, whichever
      occurs first. Participants will make multiple visits to the clinic as per regular doctor's
      appointments.
    
  